Alpha Centric Advisors LLC Tcr2 Therapeutics Inc. Transaction History

Alpha Centric Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 25, 2022	BUY	$4.58 - $8.34 $174,040 - $316,920	38,000 Added 33.63%	151,000 $704,000
Q3 2021 Mar 09, 2022	BUY	$8.44 - $18.35 $607,680 - $1.32 Million	72,000 Added 175.61%	113,000 $962,000
Q2 2021 Mar 09, 2022	BUY	$16.41 - $24.71 $582,555 - $877,205	35,500 Added 645.45%	41,000 $673,000
Q1 2021 Mar 09, 2022	BUY	$20.38 - $34.07 $65,725 - $109,875	3,225 Added 141.76%	5,500 $121,000
Q4 2020 Mar 11, 2022	BUY	$19.0 - $32.63 $7,125 - $12,236	375 Added 19.74%	2,275 $70,000
Q3 2020 Mar 11, 2022	BUY	$13.1 - $20.69 $24,890 - $39,311	1,900 New	1,900 $39,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.